Beryl Drugs Limited reported audited earnings results for the fourth quarter and full year ended March 31, 2018. For the quarter, the company reported total revenue from operations of INR 47,327,000 against INR 25,124,000 a year ago. Profit from operations before exceptional extraordinary items and tax was INR 10,504,000 against INR 5,000 a year ago. Profit before tax was INR 10,504,000 against INR 5,000 a year ago. Net profit for the period was INR 8,763,000 against loss of INR 202,000 a year ago. Basic and diluted EPS before extraordinary items was INR 1.728 against INR 0.000 a year ago. For the year, the company reported total revenue from operations of INR 159,869,000 against INR 115,284,000 a year ago. Profit from operations before exceptional extraordinary items and tax was INR 12,277,000 against loss of INR 3,605,000 a year ago. Profit before tax was INR 12,277,000 against loss of INR 3,605,000 a year ago. Net profit for the period was INR 9,929,000 or INR 1.958 per basic and diluted EPS before extraordinary items against loss of INR 4,140,000 a year ago.